Elicio Therapeutics, Inc. – NASDAQ:ELTX
Elicio Therapeutics stock price today
$11.7
+6.54
+127.18%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 6 hours
Elicio Therapeutics stock price monthly change
+12.69%
month
Elicio Therapeutics stock price quarterly change
+12.69%
quarter
Elicio Therapeutics stock price yearly change
-33.63%
year
Elicio Therapeutics key metrics
Market Cap | 53.53M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -5.79 |
Revenue | N/A |
EBITDA | -37.95M |
Income | -38.99M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeElicio Therapeutics stock price history
Elicio Therapeutics stock forecast
Elicio Therapeutics financial statements
| Jun 2023 | 0 | -7.55M | |
|---|---|---|---|
| Sep 2023 | 0 | -10.65M | |
| Dec 2023 | 0 | -8.94M | |
| Mar 2024 | 0 | -11.82M |
| 2025 | 0 | -9.51M |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 37619000 | 14.06M | 37.38% |
|---|---|---|---|
| Sep 2023 | 30987000 | 17.70M | 57.12% |
| Dec 2023 | 27146000 | 15.77M | 58.1% |
| Mar 2024 | 24480000 | 19.61M | 80.11% |
| Jun 2023 | -9.47M | 30K | 21.51M |
|---|---|---|---|
| Sep 2023 | -5.18M | -45K | 59K |
| Dec 2023 | -9.89M | 0 | 7.00M |
| Mar 2024 | -12.12M | 3K | 11.02M |
Elicio Therapeutics alternative data
| Dec 2023 | 23 |
|---|---|
| Jan 2024 | 23 |
| Feb 2024 | 23 |
| Mar 2024 | 23 |
| Apr 2024 | 23 |
| May 2024 | 32 |
| Jun 2024 | 32 |
| Jul 2024 | 32 |
Elicio Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 1032702 | 0 |
| Jun 2024 | 3300000 | 0 |
| Aug 2024 | 3442341 | 0 |
-
What's the price of Elicio Therapeutics stock today?
One share of Elicio Therapeutics stock can currently be purchased for approximately $11.7.
-
When is Elicio Therapeutics's next earnings date?
Unfortunately, Elicio Therapeutics's (ELTX) next earnings date is currently unknown.
-
Does Elicio Therapeutics pay dividends?
No, Elicio Therapeutics does not pay dividends.
-
How much money does Elicio Therapeutics make?
Elicio Therapeutics has a market capitalization of 53.53M.
-
What is Elicio Therapeutics's stock symbol?
Elicio Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ELTX".
-
What is Elicio Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Elicio Therapeutics?
Shares of Elicio Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Elicio Therapeutics have?
As Jul 2024, Elicio Therapeutics employs 32 workers, which is 39% more then previous quarter.
-
When Elicio Therapeutics went public?
Elicio Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
-
What is Elicio Therapeutics's official website?
The official website for Elicio Therapeutics is elicio.com.
-
Where are Elicio Therapeutics's headquarters?
Elicio Therapeutics is headquartered at 451 D Street, Boston, MA.
-
How can i contact Elicio Therapeutics?
Elicio Therapeutics's mailing address is 451 D Street, Boston, MA and company can be reached via phone at 857-209-0050.
Elicio Therapeutics company profile:
Elicio Therapeutics, Inc.
elicio.comExchange:
NASDAQ
Full time employees:
32
Industry:
Biotechnology
Sector:
Healthcare
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
451 D Street
Boston, MA 02210
Boston, MA 02210
CIK: 0001601485
ISIN: US28657F1030
CUSIP: 28657F103
